Bellikci-Koyu, E., Sarer-Yurekli, B
Only do this in the way your medication instructions allow
For more information on the FDA's concerns about compounded GLP-1 drugs, please refer to their official statements: Always discuss your treatment options with your healthcare provider to determine the best and safest path for your health needs
Fewer Disease Flares With GLP-1 Therapy In a retrospective study led by Shreya Sakthivel, Chief Resident of Internal Medicine at Anne Arundel Medical Center, investigators found that RA patients receiving disease-modifying antirheumatic drugs (DMARDs) who also took GLP-1 receptor agonists or SGLT2 inhibitors experienced fewer disease flares than those on DMARDs alone
, 312 , 55-61, doi: Desideri, E., Filomeni, G., and Ciriolo, M